Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy.

In the metastatic disease subgroup, cadonilimab plus chemotherapy ± bevacizumab approached significance for OS (HR = 0.73, 95%CI = 0.52–1.02, p ≈ 0.05) and reached statistical significance for PFS (HR = 0.70, 95%CI = 0.54–0.92, p < 0.05).

also in 8,237 other papers

Although the confidence intervals for both treatments included 1, cadonilimab had a strong trend toward benefit in PFS (HR = 0.65, 95%CI = 0.42–1.03), where the upper limit approached significance ( p = 0.060) compared with pembrolizumab, which did not show a clear benefit in this subgroup (HR ~ 1).

also in 5,725 other papers

However, cadonilimab showed a trend toward PFS improvement in this subgroup (HR = 0.65, 95%CI = 0.42–1.03, p = 0.06) and reached significance for PFS in the metastatic subgroup (HR = 0.70, 95%CI = 0.54–0.92, p < 0.05).

also in 53,322 other papers

In contrast, the combination of cadonilimab with bevacizumab and chemotherapy showed a trend toward benefit, but did not reach statistical significance (HR = 0.65, 95%CI = 0.41–1.02).

also in 111,027 other papers

Pembrolizumab failed to achieve significance for either endpoint.

also in 299 other papers